Ladenburg Thalmann Raises Price Target for Elicio Therapeutics
Ladenburg Thalmann sets a new $12 target for Elicio Therapeutics, maintaining a 'buy' rating.
Key Points
- Ladenburg Thalmann analyst Kevin DeGeeter raised Elicio Therapeutics' target price to $12, maintaining a 'buy' rating on June 18, 2026.
- Shares of Elicio Therapeutics (NasdaqCM: ELTX) traded at $4.71 with a market cap of approximately $89.9 million.
- Recent insider buying by key executives, including CEO Robert Connelly, reflects continued confidence in Elicio's strategic direction.
On June 18, 2026, Ladenburg Thalmann's analyst Kevin DeGeeter raised the price target for Elicio Therapeutics, Inc. (NasdaqCM: ELTX) to $12, maintaining a 'buy' rating. This update comes as shares of Elicio trade at $4.71.
Other Institutional Activity in Elicio Therapeutics
Several institutional investors have made notable moves in Elicio Therapeutics. Vanguard Capital Management LLC added 518,638 shares, bringing its total to 518,638 shares valued at approximately $5.54 million. Balyasny Asset Management L.P. increased its position by 106,052 shares to 244,814 shares worth around $2.62 million. Renaissance Technologies LLC significantly boosted its stake by 93,520 shares, ending with 121,631 shares valued at $1.30 million.
Elicio Therapeutics Stock Snapshot
Shares of Elicio Therapeutics are currently trading at $4.71. The company holds a market capitalization of about $89.9 million. The stock has experienced a 52-week low of $2.66 and a high of $16.00. Its 50-day moving average is $10.97, while the 200-day moving average is $9.97. Elicio's current ratio is 2.24, and its quick ratio is 2.07, reflecting its ability to cover short-term liabilities.
Insider Buying and Selling at Elicio Therapeutics, Inc.
Recent insider transactions at Elicio Therapeutics show significant buying activity. On February 2, 2026, several key executives, including CEO Robert Connelly, purchased shares. Connelly acquired 147,200 shares. Other notable transactions include Chief Scientific Officer Peter DeMuth buying 41,600 shares and Chief Strategy and Financial Officer Preetam Shah acquiring 47,900 shares.
Analysts Set New Price Targets
Ladenburg Thalmann assumed coverage with a 'buy' rating and a $12 target on June 18, 2026. HC Wainwright & Co. maintained its 'buy' rating with a $23 target on June 15, 2026, while B. Riley Securities initiated coverage with a 'buy' and a $27 target on June 10, 2026. The consensus recommendation for Elicio is a 'buy', with a mean target price of $23 based on one analyst opinion.
About Elicio Therapeutics
Elicio Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing immunotherapies to treat cancer. The company's lead product, ELI-002, is in Phase II clinical trials targeting specific cancer mutations. Elicio also works on other treatments such as ELI-007 and ELI-008, aiming at various cancer-related targets. The company is led by CEO Mr. Robert T. Connelly and employs 33 people.
Bottom Line
Elicio Therapeutics has caught the attention of analysts and investors alike. Ladenburg Thalmann's raised target reflects optimism about the company's future prospects. Investors keep a close watch on institutional and insider activities to gauge confidence in Elicio's strategy. It's important to remember that analyst ratings and 13F filings are backward-looking and may not reflect current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.